Loading clinical trials...
Loading clinical trials...
Turner Syndrome Minipuberty Study A Prospective, Descriptive Cohortstudy
Rationale: Due to accelerated germ cell loss, infertility is a major problem in girls with Turner syndrome (TS). Therefore, cryopreservation of ovarian tissue or oocytes before exhaustion of the ovarian reserve may preserve fertility in patients with TS. However, in the majority of females with TS , the ovarian reserve is exhausted before the age of menarche. Early markers indicating and predicting the ovarian reserve are necessary. During mid-childhood the hypothalamic-pituitary-gonadal (HPG) axis is quiescent and gonadotropins are usually unmeasurable. Nonetheless, this axis is active during infancy. Therefore, gonadotropins are measurable with peak values at 3 months of age and with lower (but still measurable) values at 9 months of age, in a period called the minipuberty. The aim of this study is to find markers of ovarian capacity, during the minipuberty, in order to predict ovarian reserve in the future. Objective: The hormonal range of LH, FSH, AMH, inhibin B, testosterone and estradiol in girls with TS during the minipuberty and the relation of the hormone serum levels with the karyotype. Study design: A prospective, cohort study with a duration of 3 years. Study population: Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study Main study parameters/endpoints: Serum levels of FSH, LH, AMH, inhibin B, testosterone and estradiol at the age of 3 and 9 months.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The subjects will have twice an extra venapunction for collection of 3.5mL blood during their infancy, which is not stated in the guidelines for TS. There is very little risk for adverse events associated with this blood sample collection, however it is an extra procedure. The outcome parameters will not be helpful for individual study participants, however they are likely to help clinicians and researchers in understanding how the ovarian function operates develops in girls with TS. Furthermore, these markers could be used to estimate the ovarian reserve and the urgency of fertility preservation in young females with TS. This information could help clinicians, patients and their parents in decision making.
Age
0 - 0 years
Sex
FEMALE
Healthy Volunteers
Yes
Righospitalet, University of Copenhagen
Copenhagen, Denmark
Universitätsklinikum der Ruhr-Universität Bochum
Bochum, Germany
Justus-Liebig Universität Giessen
Giessen, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands
Amsterdam University medical center
Amsterdam, Netherlands
University medical center Groningen
Groningen, Netherlands
Leiden University medical center
Leiden, Netherlands
Maastricht University medical center
Maastricht, Netherlands
Erasmus University medical center
Rotterdam, Netherlands
Start Date
February 1, 2020
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2024
Last Updated
November 29, 2023
30
ESTIMATED participants
Venapunction
OTHER
Lead Sponsor
Radboud University Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04872660